Dianthus Therapeutics vs Seres Therapeutics
DNTH and MCRB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DNTH and MCRB compare
Dianthus Therapeutics is the larger company, worth 369 times as much as Seres Therapeutics ($5.1B against $13.9M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DNTH | MCRB |
|---|---|---|
| Size and price | ||
| Market cap | $5.1B | $13.9M |
| Share price | $91.81 | $1.40 |
| Change, 1 year | 137% | −91.3% |
| Change, 5 years | −14.2% | −99.2% |
| Beta (5Y) | 1.44 | 1.00 |
| Employees | 92 | 66 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 6.5× |
| P/B | 4.1× | 0.7× (better) |
| FCF yield | – | −460% |
| Growth | ||
| Revenue growth (TTM) | – | 505% |
| Revenue growth, 5Y average | – | −52.7% |
| Net income growth (TTM) | – | −970% |
| EPS growth (TTM) | – | −931% |
| Profitability | ||
| Operating margin | – | −3657% |
| Net margin | – | −2210% |
| FCF margin | – | −3010% |
| Return on equity | −22.6% (better) | −144% |
| Return on invested capital | −22.2% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 30.02 (better) | 1.65 |
| Altman Z-score | 88.13 (better) | −24.76 |
| Piotroski F-score | 2 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Buyback yield | −0.01% | – |
| Shareholder yield | −0.01% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 118% | 22.9% |
| Held by insiders | 9.1% | 2.3% |
| Insider net buying, 12 months | −$75.1M | −$10.0K (better) |
| Short interest, % of float | 18.2% | 3.5% |
Go deeper
- DNTH stock overview
- DNTH income statement
- DNTH valuation and score
- MCRB stock overview
- MCRB income statement
- MCRB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.